PMID- 23614766
OWN - NLM
STAT- MEDLINE
DCOM- 20140224
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 54
IP  - 8
DP  - 2013 Aug
TI  - Overview of available p53 function tests in relation to TP53 and ATM gene 
      alterations and chemoresistance in chronic lymphocytic leukemia.
PG  - 1849-53
LID - 10.3109/10428194.2013.796058 [doi]
AB  - The ATM-p53 DNA damage response pathway plays a crucial role in chemoresistance 
      in chronic lymphocytic leukemia, as indicated by the adverse prognostic impact of 
      deletions of 17p (locus of TP53) and 11q (locus of ATM) detected by fluorescence 
      in situ hybridization (FISH) analysis. In addition to deletions, mutations in 
      these respective genes are also associated with chemoresistance, and add to the 
      prognostic information provided by FISH. In order to explore the possibility that 
      dysfunction of the ATM-p53 pathway might also result from mechanisms other than 
      ATM/TP53 deletion/mutation, assays have been developed that probe the functional 
      integrity of the ATM-p53 pathway. Currently, four different p53 function assays 
      have been developed that are based on the measurement of p53 and p53-dependent 
      genes at the RNA (real-time polymerase chain reaction [RT-PCR]p21; RT-PCRmiR34a; 
      reverse transcription-multiplex ligation-dependent probe amplification assay 
      [RT-MLPA]p21, bax, puma and CD95) or protein (fluorescence activated cell sorting 
      [FACS]p53-p21) level in untreated cells or following irradiation or drug 
      treatment. Here we provide an overview of these assays based on the available 
      literature.
FAU - te Raa, G Doreen
AU  - te Raa GD
AD  - Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.
FAU - Malcikova, Jitka
AU  - Malcikova J
FAU - Pospisilova, Sarka
AU  - Pospisilova S
FAU - Trbusek, Martin
AU  - Trbusek M
FAU - Mraz, Mark
AU  - Mraz M
FAU - Garff-Tavernier, Maria Le
AU  - Garff-Tavernier ML
FAU - Merle-Beral, Helene
AU  - Merle-Beral H
FAU - Lin, Ke
AU  - Lin K
FAU - Pettitt, Andrew R
AU  - Pettitt AR
FAU - Merkel, Olaf
AU  - Merkel O
FAU - Stankovic, Tatjana
AU  - Stankovic T
FAU - van Oers, Marinus H
AU  - van Oers MH
FAU - Eldering, Eric
AU  - Eldering E
FAU - Stilgenbauer, Stephan
AU  - Stilgenbauer S
FAU - Zenz, Thorsten
AU  - Zenz T
FAU - Kater, Arnon P
AU  - Kater AP
CN  - European Research Initiative on CLL (ERIC)
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130624
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.11.1 (Ataxia Telangiectasia Mutated Proteins)
SB  - IM
MH  - Ataxia Telangiectasia Mutated Proteins/*genetics
MH  - *Drug Resistance, Neoplasm/genetics
MH  - Flow Cytometry/methods
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/*genetics/*metabolism
MH  - Polymerase Chain Reaction/methods
MH  - Signal Transduction
MH  - Tumor Suppressor Protein p53/*genetics/*metabolism
EDAT- 2013/04/26 06:00
MHDA- 2014/02/25 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/26 06:00 [entrez]
PHST- 2013/04/26 06:00 [pubmed]
PHST- 2014/02/25 06:00 [medline]
AID - 10.3109/10428194.2013.796058 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2013 Aug;54(8):1849-53. doi: 10.3109/10428194.2013.796058. Epub 
      2013 Jun 24.